Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GrB-Fc-4D5
- Development stage
- Preclinical
- Lead developer
- AbBC Therapies
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GrB-Fc-4D5 is a preclinical-stage biologic fusion protein being developed by AbBC Therapies for the treatment of HER2/Neu-expressing cancers, including breast, gallbladder, bladder, esophageal/gastric junction, and stomach cancers. The construct comprises a humanized anti-HER2 single-chain variable fragment (scFv) derived from the 4D5 antibody, linked via an IgG-Fc domain to active granzyme B (GrB), a serine protease. This design enables the fusion protein to specifically bind to HER2-positive tumor cells and internalize, delivering granzyme B to the cytoplasm where it triggers apoptosis through multiple pathways. This mechanism mimics natural T-cell and NK-cell mediated cytotoxicity without the requirement for perforin-mediated membrane pore formation.
- Other names
- Granzyme B-Fc-4D5 fusion proteinanti-HER2-GrB-Fcanti-HER-2-GrB-Fcanti-HER 2-GrB-Fc
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GrB-Fc-4D5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GrB-Fc-4D5.